HRP20210575T1 - Imunogeni pripravci bakterije bordetella bronchiseptica - Google Patents
Imunogeni pripravci bakterije bordetella bronchiseptica Download PDFInfo
- Publication number
- HRP20210575T1 HRP20210575T1 HRP20210575TT HRP20210575T HRP20210575T1 HR P20210575 T1 HRP20210575 T1 HR P20210575T1 HR P20210575T T HRP20210575T T HR P20210575TT HR P20210575 T HRP20210575 T HR P20210575T HR P20210575 T1 HRP20210575 T1 HR P20210575T1
- Authority
- HR
- Croatia
- Prior art keywords
- canine
- accordance
- preparation
- immunogenic preparation
- intended
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 15
- 241000588779 Bordetella bronchiseptica Species 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 241000282465 Canis Species 0.000 claims 10
- 244000052769 pathogen Species 0.000 claims 7
- 241001353878 Canine parainfluenza virus Species 0.000 claims 6
- 241001594994 Canine respiratory coronavirus Species 0.000 claims 6
- 230000001717 pathogenic effect Effects 0.000 claims 6
- 230000000241 respiratory effect Effects 0.000 claims 6
- 241000701114 Canine adenovirus 2 Species 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- 101150047856 Cav2 gene Proteins 0.000 claims 2
- 241000694560 Mycoplasma cynos Species 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/098—Brucella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Claims (14)
1. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije psećim respiratornim patogenom kod psa, naznačen time što pripravak sadrži bakterin iz bakterije Bordetella bronchiseptica i dodani izolirani protein p68 iz bakterije Bordetella bronchiseptica, gdje je navedeni p68 prisutan u količini između 5 µg ± 10% i 20 µg ± 10%.
2. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeni p68 prisutan u količini od 10 µg ± 10%.
3. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što dodatno sadrži veterinarski prihvatljivi nosač, u volumenu između 1 ml i 4 ml.
4. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeni p68 prisutan u količini od 7 µg ± 10% do 15 µg ± 10%.
5. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što je navedeni volumen 2 ml ± 10%.
6. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što je navedeni volumen 1 ml.
7. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pripravak sprječava infekciju navedenim psećim respiratornim patogenom kod navedenog psa u trajanju od najmanje šest mjeseci.
8. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pripravak dodatno sadrži razrjeđivač ili pomoćno sredstvo namijenjeno parenteralnoj primjeni na psu.
9. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pripravak dodatno sadrži izolirani antigen Bsp22, koji može biti lipidiran.
10. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni pripravak dodatno sadrži antigen iz psećeg respiratornog patogena kojeg se bira iz skupine koju čine: virus pseće parainfluence (CPIV), pseći adenovirus-2 (CAV-2), pseći respiratorni koronavirus (CRCoV), Mycoplasma cynos (M. cynos) i virus pseće influence (CIV).
11. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što navedeni pripravak sadrži najmanje dva, tri ili četiri antigena iz psećeg respiratornog patogena.
12. Imunogeni pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što navedeni pripravak sadrži antigene iz virusa pseće parainfluence (CPIV), psećeg adenovirusa-2 (CAV-2), psećeg respiratornog koronavirusa (CRCoV) i virusa pseće influence (CIV).
13. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što pseći respiratorni patogen dodatno sadrži najmanje jedan, dva, tri ili četiri od: virusa pseće parainfluence (CPIV), psećeg adenovirusa-2 (CAV-2), psećeg respiratornog koronavirusa (CRCoV) i virusa pseće influence (CIV).
14. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je pseći respiratorni patogen kompleks psećih zaraznih respiratornih bolesti (CIRDC), gdje pripravak liječi ili sprječava infekciju od strane više navedenih patogena.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161439597P | 2011-02-04 | 2011-02-04 | |
| EP12705438.5A EP2670432B1 (en) | 2011-02-04 | 2012-02-03 | Immunogenic bordetella bronchiseptica compositions |
| PCT/IB2012/050512 WO2012104821A1 (en) | 2011-02-04 | 2012-02-03 | Immunogenic bordetella bronchiseptica compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210575T1 true HRP20210575T1 (hr) | 2021-05-28 |
Family
ID=45755432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210575TT HRP20210575T1 (hr) | 2011-02-04 | 2021-04-12 | Imunogeni pripravci bakterije bordetella bronchiseptica |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130302369A1 (hr) |
| EP (2) | EP3858381A1 (hr) |
| JP (1) | JP5833145B2 (hr) |
| KR (1) | KR101647180B1 (hr) |
| CN (2) | CN103561763A (hr) |
| AU (2) | AU2012213035A1 (hr) |
| BR (1) | BR112013019675B8 (hr) |
| CA (1) | CA2826060C (hr) |
| CL (1) | CL2013002219A1 (hr) |
| CO (1) | CO6791568A2 (hr) |
| CY (1) | CY1124093T1 (hr) |
| DK (1) | DK2670432T3 (hr) |
| ES (1) | ES2869175T3 (hr) |
| HK (1) | HK1245676A1 (hr) |
| HR (1) | HRP20210575T1 (hr) |
| HU (1) | HUE055669T2 (hr) |
| LT (1) | LT2670432T (hr) |
| MX (1) | MX347177B (hr) |
| PL (1) | PL2670432T3 (hr) |
| PT (1) | PT2670432T (hr) |
| RS (1) | RS61723B1 (hr) |
| RU (1) | RU2554480C2 (hr) |
| SI (1) | SI2670432T1 (hr) |
| UA (2) | UA110504C2 (hr) |
| WO (1) | WO2012104821A1 (hr) |
| ZA (1) | ZA201306615B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850296C (en) | 2011-10-03 | 2021-01-12 | Moreinx Ab | Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
| NZ701930A (en) * | 2012-05-31 | 2016-10-28 | Zoetis Llc | Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections |
| CA3005608C (en) | 2013-09-19 | 2020-06-30 | Zoetis Services Llc | Water-in-oil emulsions comprising immunostimulatory oligonucleotides |
| EP3074003B1 (en) * | 2013-11-26 | 2023-01-11 | Zoetis Services LLC | Compositions for induction of immune response |
| KR20170097116A (ko) | 2015-01-16 | 2017-08-25 | 조에티스 서비시즈 엘엘씨 | 구제역 백신 |
| EP3909971A1 (en) | 2020-09-28 | 2021-11-17 | Institute of Life Sciences (ILS) | Whole cell livestock vaccine for respiratory diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2571618A1 (fr) | 1984-10-12 | 1986-04-18 | Virbac Ctre Rech Biolog | Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation |
| US5019388A (en) * | 1986-10-14 | 1991-05-28 | Norden Laboratories Inc. | Bordetella bronchiseptica vaccine |
| US4888169A (en) * | 1986-10-14 | 1989-12-19 | Norden Laboratories, Inc. | Bordetella Bronchiseptica vaccine |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE325621T1 (de) * | 1996-05-31 | 2006-06-15 | Nat Univ Ireland Maynooth | Il-12 als adjuvanz für bordetella pertussis impfstoffe |
| SK283565B6 (sk) * | 1996-07-02 | 2003-09-11 | Connaught Laboratories Limited | Multivalentná imunogénna kompozícia a jej použitie |
| DE60133734T2 (de) * | 2000-05-25 | 2009-05-14 | Institut Pasteur | Polypeptide die polymorphismen aus bordertella pertussis, bordetella parapertussis und bordetella bronchiseptica pertactin wiederholende regionen enthalten, ihre verwendung in diagnostik und immunogene zusammensetzungen |
| GB0217434D0 (en) * | 2002-07-27 | 2002-09-04 | Royal Vetinary College | Biological material |
| KR20050103215A (ko) * | 2003-01-29 | 2005-10-27 | 화이자 프로덕츠 인코포레이티드 | 보르데텔라 브론키셉티카에 대한 개 백신 |
| US20050089533A1 (en) * | 2003-01-29 | 2005-04-28 | Joseph Frantz | Canine vaccines against Bordetella bronchiseptica |
| GB0315323D0 (en) | 2003-07-01 | 2003-08-06 | Royal Veterinary College | Vaccine composition |
| ES2346314T3 (es) * | 2003-10-02 | 2010-10-14 | Glaxosmithkline Biolog Sa | Antigenos de b. pertussis y uso de los mismos en vacunacion. |
| US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
| AU2006231916A1 (en) * | 2005-04-07 | 2006-10-12 | Pharmacia & Upjohn Company Llc | Formulations and process for production of Bordetella bronchiseptica p68 antigen and vaccines |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US7384642B2 (en) | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
| NZ566490A (en) * | 2005-10-07 | 2011-06-30 | Pfizer Prod Inc | Live attenuated or killed H3N8 influenza vaccines and methods to treat canine influenza |
| US7468187B2 (en) * | 2005-10-18 | 2008-12-23 | Iowa State University Research Foundation, Inc. | Canine influenza virus and related compositions and methods of use |
| EP1941033A2 (en) * | 2005-10-20 | 2008-07-09 | Wyeth a Corporation of the State of Delaware | Compositions and methods for the treatment of canine influenza virus disease |
| US7682619B2 (en) * | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| NZ572808A (en) * | 2006-05-19 | 2011-11-25 | Water And Eliza Hall Inst Of Medical Res | Compositions for raising an immune response comprising an antigen and a targeting moiety for lymph-resident dendritic cells |
-
2012
- 2012-02-03 CN CN201280015807.1A patent/CN103561763A/zh active Pending
- 2012-02-03 EP EP21162470.5A patent/EP3858381A1/en active Pending
- 2012-02-03 SI SI201231911T patent/SI2670432T1/sl unknown
- 2012-02-03 BR BR112013019675A patent/BR112013019675B8/pt active IP Right Grant
- 2012-02-03 ES ES12705438T patent/ES2869175T3/es active Active
- 2012-02-03 MX MX2013009012A patent/MX347177B/es active IP Right Grant
- 2012-02-03 DK DK12705438.5T patent/DK2670432T3/da active
- 2012-02-03 PT PT127054385T patent/PT2670432T/pt unknown
- 2012-02-03 WO PCT/IB2012/050512 patent/WO2012104821A1/en active Application Filing
- 2012-02-03 LT LTEP12705438.5T patent/LT2670432T/lt unknown
- 2012-02-03 PL PL12705438T patent/PL2670432T3/pl unknown
- 2012-02-03 RS RS20210474A patent/RS61723B1/sr unknown
- 2012-02-03 RU RU2013136151/10A patent/RU2554480C2/ru active
- 2012-02-03 HU HUE12705438A patent/HUE055669T2/hu unknown
- 2012-02-03 CA CA2826060A patent/CA2826060C/en active Active
- 2012-02-03 CN CN201710294793.6A patent/CN107296955B/zh active Active
- 2012-02-03 US US13/983,127 patent/US20130302369A1/en active Pending
- 2012-02-03 AU AU2012213035A patent/AU2012213035A1/en not_active Abandoned
- 2012-02-03 JP JP2013552317A patent/JP5833145B2/ja active Active
- 2012-02-03 EP EP12705438.5A patent/EP2670432B1/en active Active
- 2012-02-03 KR KR1020137022854A patent/KR101647180B1/ko active IP Right Grant
- 2012-03-02 UA UAA201309552A patent/UA110504C2/ru unknown
- 2012-03-02 UA UAA201309553A patent/UA110505C2/ru unknown
-
2013
- 2013-08-02 CL CL2013002219A patent/CL2013002219A1/es unknown
- 2013-08-02 CO CO13184705A patent/CO6791568A2/es not_active Application Discontinuation
- 2013-09-03 ZA ZA2013/06615A patent/ZA201306615B/en unknown
-
2014
- 2014-04-10 HK HK18105491.3A patent/HK1245676A1/zh unknown
-
2017
- 2017-05-15 AU AU2017203244A patent/AU2017203244B2/en active Active
-
2021
- 2021-04-12 HR HRP20210575TT patent/HRP20210575T1/hr unknown
- 2021-05-06 CY CY20211100386T patent/CY1124093T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210575T1 (hr) | Imunogeni pripravci bakterije bordetella bronchiseptica | |
| HRP20190876T1 (hr) | Novi adjuvantirani pripravci | |
| EA201201321A1 (ru) | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний | |
| HRP20160276T1 (hr) | Pripravci za imuniziranje protiv bakterije staphylococcus aureus | |
| BR112014004860A2 (pt) | composições de anticorpo contra vírus da influenza | |
| CL2015001304A1 (es) | Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos. | |
| CO6491048A2 (es) | Inhibidores de la replicación de los virus de la gripe | |
| CO6761399A2 (es) | Composiciones y métodos de vacuna del virus tipo 1b de diarrea viral bovina | |
| BR112015013513A8 (pt) | Composição imunogênica multivalente; e composição farmacêutica para induzir uma resposta imunológica aos conjugados de polissacarídeo capsular de streptococcus pneumoniae | |
| MX2013013906A (es) | Vacunas combinadas para prevencion de infecciones por virus porcino. | |
| BR112013002296A2 (pt) | composição farmacêutica e respectivo uso e método para tratar doença infecciosa | |
| BR112013026661A2 (pt) | método de entrega de vacina | |
| WO2010040710A1 (en) | Vaccine composition for use against influenza | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| AR051636A1 (es) | Vacunas multivalentes para la gripe aviar | |
| CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| HRP20211308T1 (hr) | Veterinarski postupak za izazivanje emeze | |
| RU2013135887A (ru) | Композиции для комплекса респираторных заболеваний собак | |
| BR112013023354A2 (pt) | vacina para rinite equina | |
| RU2012143152A (ru) | Способ защиты от заболеваний, вызываемых вторичными патогенами | |
| RU2008130944A (ru) | Гипериммунная поливалентная сыворотка против массовых вирусных болезней крупного рогатого скота (спви-крс) и способ ее применения | |
| Lee et al. | Adjuvant efficacy of mOMV against avian influenza virus infection in mice | |
| AR078147A1 (es) | Regimen de inmunizacion por sensibilizacion - refuerzo heterologa | |
| CL2007001713A1 (es) | Composicion farmaceutica oral en forma de suspension acuosa que comprende particulas del antihelmintico carbamato de bencimidazol con un 90% de tamano promedio menor que 450 nm y un surfactante polisorbato; metodo para su preparcion; metodo para preparar un medicamento; y uso para controlar infecciones parasitarias en animales. | |
| UA25751U (en) | Inactivated emulsified vaccine against avian influenza and newcastle disease associated from a/chicken/syvash and lg-85 strains |